Plain-English translation of NCT05327686 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The SAMURAI trial is testing whether combining stereotactic ablative radiation therapy (SABR)—a highly focused form of radiation delivered in just a few sessions—with standard immunotherapy works better than immunotherapy alone for advanced kidney cancer. You would receive one of several immunotherapy regimens (such as and , or and , among others, chosen by your doctor based on your specific situation). Half of participants will receive only the immunotherapy, while the other half will also receive the focused radiation treatment directly to the kidney tumor over 1–3 weeks.
Currently, people with advanced kidney cancer that cannot be surgically removed are treated with immunotherapy alone. Researchers want to know whether adding focused radiation directly to the tumor might help the immunotherapy work better and improve how long patients survive without their cancer getting worse.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either immunotherapy alone or immunotherapy plus focused radiation therapy. If assigned to receive radiation, you will come in for 3 radiation treatment sessions over 1–3 weeks. All participants will receive immunotherapy either as an infusion every 2–6 weeks (depending on the specific medication) or as a daily pill, continuing as long as it is working and you can tolerate it. Throughout the trial, you will have regular CT or MRI scans to monitor how your cancer is responding, blood tests to check your health, and follow-up appointments with your medical team. The trial is enrolling about 240 participants across multiple hospitals and cancer centers.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States